Benzinga | Jan 24, 2022 04:12PM EST

89bio Reports Topline Results From An Expansion Cohort Of The Phase 1b/2a Trial Of Pegozafermin For The Treatment Of NASH

* 63% of patients achieved 2-point or greater improvement in NAS without worsening of fibrosis; clinically meaningful improvements on registration enabling endpoints of NASH resolution (32%) and fibrosis improvement (26%)

* Robust changes on multiple non-invasive liver tests, markers of cardiovascular health and glycemic control support pegozafermin's potential as a compelling treatment option for NASH

* Phase 2b ENLIVEN trial ongoing in NASH patients with results expected in first half 2023

* Conference call and webcast today at 1:30 p.m. PST/4:30 p.m. EST